GH Research PLC 4

Duncan Moore was awarded 2,202 share options of GH Research PLC, each for an Ordinary Share at a $0.025 exercise price.

On August 11, 2026, Duncan Moore received a grant of 2,202 share options of GH Research PLC, each representing the right to buy an Ordinary Share at an exercise price of $0.025 per share. The options are immediately fully vested but are not exercisable until August 11, 2028, and they expire on August 11, 2033. This award increased Moore’s derivative holdings by 2,202 options, corresponding to 2,202 underlying Ordinary Shares, with no cash paid or received at grant. Using the stated exercise price as a proxy, the notional value of the grant at strike is approximately $55, though the economic value will depend on GH Research’s share price when the options become exercisable.

Filing Facts

CIK

1855129

Ticker

GHRS

Form

4

Source Type

fda

Accession

0001140361-26-032856

Alert Tier

4